ArticleCancers2022

Systemic Inflammation Index and Tumor Glycolytic Heterogeneity Help Risk Stratify Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitor Therapy.

Kun-Han Lue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.